CoChat
Sign Up
Cited by 510Ovarian cancer diagnosis and treatmentBRCA gene mutations in cancerBreast Lesions and Carcinomas

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study

Open access
Van Calster, B., Van Hoorde, K., Valentin, L., Testa, A. C., Fischerova, D., Van Holsbeke, C., Savelli, L., Franchi, D., Epstein, E., Kaijser, J., Van Belle, V., Czekierdowski, A., Guerriero, S., Fruscio, R., Lanzani, C., Scala, F., Bourne, T., Timmerman, D., International Ovarian Tumour Analysis (IOTA) group·2014·BMJ
DOI 10.1136/bmj.g5920PMC PMC4198550
Open this paper in CoChat — free accountOpen PDF

Abstract

OBJECTIVES: To develop a risk prediction model to preoperatively discriminate between benign, borderline, stage I invasive, stage II-IV invasive, and secondary metastatic ovarian tumours. DESIGN: Observational diagnostic study using prospectively collected clinical and ultrasound data. SETTING: 24 ultrasound centres in 10 countries. PARTICIPANTS: Women with an ovarian (including para-ovarian and tubal) mass and who underwent a standardised ultrasound examination before surgery. The model was developed on 3506 patients recruited between 1999 and 2007, temporally validated on 2403 patients recruited between 2009 and 2012, and then updated on all 5909 patients. MAIN OUTCOME MEASURES: Histological classification and surgical staging of the mass. RESULTS: The Assessment of Different NEoplasias in the adneXa (ADNEX) model contains three clinical and six ultrasound predictors: age, serum CA-125 level, type of centre (oncology centres v other hospitals), maximum diameter of lesion, proportion of solid tissue, more than 10 cyst locules, number of papillary projections, acoustic shadows, and ascites. The area under the receiver operating characteristic curve (AUC) for the classic discrimination between benign and malignant tumours was 0.94 (0.93 to 0.95) on temporal validation. The AUC was 0.85 for benign versus borderline, 0.92 for benign versus stage I cancer, 0.99 for benign versus stage II-IV cancer, and 0.95 for benign versus secondary metastatic. AUCs between malignant subtypes varied between 0.71 and 0.95, with an AUC of 0.75 for borderline versus stage I cancer and 0.82 for stage II-IV versus secondary metastatic. Calibration curves showed that the estimated risks were accurate. CONCLUSIONS: The ADNEX model discriminates well between benign and malignant tumours and offers fair to excellent discrimination between four types of ovarian malignancy. The use of ADNEX has the potential to improve triage and management decisions and so reduce morbidity and mortality associated with adnexal pathology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmj.g5920

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 57 references

Cited by

Sorted by citations

Items 501–510 of 510

Related

See all

Metadata

Authors
Van Calster, B., Van Hoorde, K., Valentin, L., Testa, A. C., Fischerova, D., Van Holsbeke, C., Savelli, L., Franchi, D., Epstein, E., Kaijser, J., Van Belle, V., Czekierdowski, A., Guerriero, S., Fruscio, R., Lanzani, C., Scala, F., Bourne, T., Timmerman, D., & International Ovarian Tumour Analysis (IOTA) group
Affiliations
  • Lund University (SE)
  • Università Cattolica del Sacro Cuore (IT)
  • IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
  • European Institute of Oncology (IT)
  • Karolinska University Hospital (SE)
  • Universitair Ziekenhuis Leuven (BE)
  • Medical University of Lublin (PL)
  • Azienda Ospedaliero-Universitaria Cagliari (IT)
  • University of Milan (IT)
  • Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
ORCID
Venue
BMJ
Publisher
BMJ
Published
2014-10-15
Volume
349
Issue
oct07 3
Pages
g5920-g5920
ISSN
1756-1833 (ISSN-L)
DOI
10.1136/bmj.g5920
PMC
PMC4198550
OpenAlex
W2099878111
Cited by
510
References
57
Citations by year
2026: 52 · 2025: 60 · 2024: 70 · 2023: 54 · 2022: 55 · 2021: 59 · 2020: 36 · 2019: 24 · 2018: 30 · 2017: 19 · 2016: 27 · 2015: 19 · 2014: 4
FWCI
27.87
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • BMJ (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • BOA (University of Milano-Bicocca) (submittedVersion, cc-by-nc)
  • Lirias (KU Leuven) (submittedVersion, cc-by-nc)
  • UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion, other-oa)
  • Lund University Publications (Lund University) (submittedVersion, other-oa)
  • HighWire Press Open Archive (submittedVersion)
  • PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, cc-by-nc)
  • Spiral (Imperial College London) (submittedVersion, other-oa)
Funders
  • National Institute for Health and Care Research
  • Imperial College London
  • Imperial College Healthcare NHS Trust
  • Fonds Wetenschappelijk Onderzoek (G049312N)
  • iMinds
  • Malmö Högskola
  • Skånes universitetssjukhus
  • Vlaamse regering (G049312N)
  • Medical Research Council
Topics
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
Keywords
ovarian cancer, ADNEX model, preoperative risk prediction, ovarian ultrasonography, borderline ovarian tumors, CA125, surgical staging, adnexal mass, triage
MeSH terms
Adnexal Diseases, Adult, Female, Humans, Neoplasm Staging, Ovarian Neoplasms, Predictive Value of Tests, Prospective Studies, Ultrasonography, Models, Statistical, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review